Trimethoxy-benzaldehyde levofloxacin hydrazone inducing the growth arrest and apoptosis of human hepatocarcinoma cells

Cancer Cell International

Bin Liu²  Jin-bo Deng²  Chao-shen Huangfu²  Guo-qiang Hu³  Yu-hua Kang¹  Shi-meng Liu¹  Zhen-yu Shi²  Jin-ping Sun¹ 

[1] Huaihe Clinical College, Henan University, Kaifeng, China;College of Nursing, Institute of Neurobiology, Henan University, Kaifeng, China;Institute of Chemical Biology, Henan University, Kaifeng, China

关键词: Apoptosis;    Mitochondrial dysfunction;    DNA topoisomerase II;    Hepatocarcinoma cell line;    Fluoroquinolone derivatives;   

Others  :  793449
DOI  :  10.1186/1475-2867-13-67

 received in 2013-02-21, accepted in 2013-06-25,  发布年份 2013

【 摘 要 】

Background

In order to search for new structural modification strategies on fluoroquinolones, we have designed and synthesized a series of fluoroquinolone derivatives by linking various hydrazine compounds to the C-3 carboxyl group of levofloxacin and assessed their anticancer activities. Several novel levofloxacin derivatives displayed potent cytotoxicity against the tested cancer cell lines in vitro. In the present study, we investigated the effect of 1-Cyclopropyl-6-fluoro-4-oxo-7- piperazin-1, 4-dihydro- quinoline- 3-carboxylic acid benzo [1,3] dioxol-5- ylmethylene- hydrazide (QNT11) on the apoptosis of human hepatocarcinoma cells in vitro.

Methods

The inhibition effects of QNT11 on cell proliferation were examined by MTT assay. Cell apoptosis was determined by TUNEL and DNA agarose gel electrophoresis method. The topoisomerase ΙΙ activity was measured by agarose gel electrophoresis using Plasmid pBR322 DNA as the substrate. Cell cycle progression was analyzed using flow cytometry in conjunction with ethanol fixation and propidium iodide staining. Mitochondrial membrane potential (△ψm) was measured by high content screening image system. The caspase-9, caspase-8, caspase-3, Bcl-2, Bax, CDK1, Cyclin B1and cytochrome c protein expressions were detected by Western blot analysis.

Results

QNT11 showed selective cytotoxicity against Hep3B, SMMC-7721, MCF-7 and HCT-8 cell lines with IC₅₀ values of 2.21 μM, 2.38 μM, 3.17 μM and 2.79 μM, respectively. In contrast, QNT11 had weak cytotoxicity against mouse bone marrow mesenchymal stem cells (BMSCs) with IC₅₀ value of 7.46 μM. Treatment of Hep3B cells with different concentrations of QNT11 increased the percentage of the apoptosis cells significantly, and agarose gel electrophoresis revealed the ladder DNA bands typical of apoptotic cells, with a decrease in the mitochondrial membrane potential. Compared to the control group, QNT11 could influence the DNA topoisomerase IIactivity and inhibit the religation of DNA strands, thus keeping the DNA in fragments. There was a significant increase of cytochrome c in the cytosol after 24 h of treatment with QNT11 and a decrease in the mitochondrial compartment. Observed changes in cell cycle distribution by QNT11 treated might be caused by insufficient preparation for G₂/M transition. In addition, QNT11 increased the protein expression of Bax, caspase-9, caspase-8, caspase-3, as well as the cleaved activated forms of caspase-9, caspase-8 and caspase-3 significantly, whereas the expression of Bcl-2 decreased.

Conclusions

Our results showed that QNT11 as a fluoroquinolone derivative exerted potent and selectively anticancer activity through the mechanism of eukaryotic topoisomerase II poisoning. The growth inhibition was in large part mediated via apoptosis-associated mitochondrial dysfunction and regulation of Bcl-2 signaling pathways.

【 授权许可】

   
2013 Sun et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Ahmed A, Daneshtalab M: Nonclassical biological activities of quinolone derivatives. J Pharm Pharm Sci 2012, 15:52-72.
• [2]Bax BD, Chan PF, Eggleston DS, Fosberry A, Gentry DR, Gorrec F, Giordano I, Hann MM, Hennessy A, Hibbs M, Huang J, Jones E, Jones J, Brown KK, Lewis CJ, May EW, Saunders MR, Singh O, Spitzfaden CE, Shen C, Shillings A, Theobald AJ, Wohlkonig A, Pearson ND, Gwynn MN: Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 2010, 466:935-940.
• [3]Rajabalian S, Foroumadi A, Shafiee A, Emami S: Functionalized N-(2-oxyiminoethyl) piperazinyl quinolones as new cytotoxic agents. J Pharm Pharm Sci 2007, 10:153-158.
• [4]Yamashita Y, Ashizawa T, Morimoto M, Hosomi J, Nakano H: Antitumor quinolones with mammalian topoisomerase II mediated DNA cleavage activity. Cancer Res 1992, 52:2818-2822.
• [5]Kloskowski T, Gurtowska N, Nowak M, Joachimiak R, Bajek A, Olkowska J, Drewa T: The influence of ciprofloxacin on viability of A549, HepG2, A375. S2, B16 and C6 cell lines in vitro. Acta Pol Pharm 2011, 68:859-865.
• [6]Koziel R, Szczepanowska J, Magalska A, Piwocka K, Duszynski J, Zablocki K: Ciprofloxacin inhibits proliferation and promotes generation of aneuploidy in Jurkat cells. J Physiol Pharmacol 2010, 61:233-239.
• [7]Hawtin RE, Stockett DE, Byl JA, McDowell RS, Nguyen T, Arkin MR, Conroy A, Yang W, Osheroff N, Fox JA: Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLoS One 2010, 5:e10186.
• [8]Azéma J, Guidetti B, Korolyov A, Kiss R, Roques C, Constant P, Daffé M, Malet-Martino M: Synthesis of lipophilic dimeric C-7/C-7-linked ciprofloxacin and C-6/C-6-linked levofloxacin derivatives. Versatile in vitro biological evaluations of monomeric and dimeric fluoroquinolone derivatives as potential antitumor, antibacterial or antimycobacterial agents. Eur J Med Chem 2011, 46:6025-6038.
• [9]Foroumadi A, Emami S, Rajabalian S, Badinloo M, Mohammadhosseini N, Shafiee A: N-Substituted piperazinyl quinolones as potential cytotoxic agents: structure-activity relationships study. Biomed Pharmacother 2009, 63:216-220.
• [10]You QD, Li ZY, Huang CH, Yang Q, Wang XJ, Guo QL, Chen XG, He XG, Li TK, Chern JW: Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification. J Med Chem 2009, 52:5649-5661.
• [11]Shi ZY, Li YQ, Kang YH, Hu GQ, Huang-fu CS, Deng JB, Liu B: Piperonal ciprofloxacin hydrazone induces growth arrest and apoptosis of human hepatocarcinoma SMMC-7721 cells. Acta Pharmacol Sin 2012, 33:271-278.
• [12]Kumar D, Sundaree S, Johnson EO, Shah K: An efficient synthesis and biological study of novel indolyl-1, 3, 4-oxadiazoles as potent anticancer agents. Bioorg Med Chem Lett 2009, 19:4492-4494.
• [13]Robinson MJ, Martin BA, Gootz TD, McGuirk PR, Moynihan M, Sutcliffe JA, Osheroff N: Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage. J Biol Chem 1991, 266:14585-14592.
• [14]Pommier Y, Leo E, Zhang H: Marchand C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 2010, 17:421-433.
• [15]Kumar N, Raj VP, Jayshree BS, Kar SS, Anandam A, Thomas S, Jain P, Rai A, Rao CM: Elucidation of structure-activity relationship of 2-quinolone derivatives and exploration of their antitumor potential through Bax-induced apoptotic pathway. Chem Biol Drug Des 2012, 80:291-299.
• [16]Mondal ER, Das SK, Mukherjee P: Comparative evaluation of antiproliferative activity and induction of apoptosis by some fluoroquinolones with a human non-small cell lung cancer cell line in culture. Asian Pac J Cancer Prev 2004, 5:196-204.
• [17]Hammonds TR, Foster SR, Maxwell A: Increased sensitivity to quinolone antibacterials can be engineered in human topoisomerase II alpha by selective mutagenesis. J Mol Biol 2000, 300:481-491.
• [18]Roychoudhury S, Makin KM, Twinem TL, Stanton DT, Nelson SL, Catrenich CE: Development and use of a high-throughput bacterial DNA gyrase assay to identify mammalian topoisomerase II inhibitors with whole-cell anticancer activity. J Biomol Screen 2003, 8:157-163.
• [19]Elsea SH, Osheroff N, Nitiss JL: Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115, 953 in yeast. J Biol Chem 1992, 267:13150-13153.
• [20]Nitiss JL: Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009, 9:338-350.
• [21]Elsea SH, McGuirk PR, Gootz TD, Moynihan M, Osheroff N: Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential. Antimicrob Agents Chemother 1993, 37:2179-2186.
• [22]Walsby EJ, Coles SJ, Knapper S, Burnett AK: The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine. Haematologica 2011, 96:393-399.
• [23]Yogeeswari P, Sriram D, Kavya R, Tiwari S: Synthesis and in-vitro cytotoxicity evaluation of gatifloxacin Mannich bases. Biomed Pharmacother 2005, 59:501-510.
• [24]Aranha O, Grignon R, Fernandes N, McDonnell TJ, Wood DP Jr, Sarkar FH: Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis. Int J Oncol 2003, 22:787-794.
• [25]Huang SM, Yang JS, Tsai SC, Chen MH, Hsu MH, Lin HY, Chou LC, Chinag JH, Lee KH, Huang LJ, Kuo SC: The novel synthesized 2-(3-(methylamino) henyl)-6-(pyrrolidin-1-yl)quinolin-4-one (Smh-3) compound induces G2/M phase arrest and mitochondrial-dependent apoptotic cell death through inhibition of CDK1 and AKT activity in HL-60 human leukemia cells. Int J Oncol 2011, 38:1357-1364.
• [26]Plati J, Bucur O, Khosravi-Far R: Apoptotic cell signaling in cancer progression and therapy. Integr Biol (Camb) 2011, 3:279-296.
• [27]Mason EF, Rathmell JC: Cell metabolism: an essential link between cell growth and apoptosis. Biochim Biophys Acta 1813, 2011:645-654.
• [28]Ko JK, Choi KH, Peng J, He F, Zhang Z, Weisleder N, Lin J, Ma J: Amphipathic tail-anchoring peptide and Bcl-2 homology domain-3 (BH3) peptides from Bcl-2 family proteins induce apoptosis through different mechanisms. J Biol Chem 2011, 286:9038-9048.
• [29]Zhao Q, Cao X, Zeng B, Wang C, Yan L, Xu C: Musca domestica larva lectin induces apoptosis in BEL-7402 cells through a mitochondria-mediated reactive oxygen species way. Biol Pharm Bull 2010, 33:1274-1278.
• [30]Hsu SC, Yang JS, Kuo CL, Lo C, Lin JP, Hsia TC, Lin JJ, Lai KC, Kuo HM, Huang LJ, Kuo SC, Wood WG, Chung JG: Novel quinolone CHM-1 induces apoptosis and inhibits metastasis in a human osterogenic sarcoma cell line. J Orth-op Res 2009, 27:1637-1644.
• [31]Patil JB, Kim J, Jayaprakasha GK: Berberine induces apoptosis in breast cancer cells (MCF-7) through mitochondrial-dependent pathway. Eur J Pharmacol 2010, 645:70-78.
• [32]Chang YH, Yang JS, Kuo SC, Chung JG: Induction of mitotic arrest and apoptosis by a novel synthetic quinolone analogue, CWC-8, via intrinsic and extrinsic apoptotic pathways in human osteogenic sarcoma U-2 OS cells. Anticancer Res 2009, 29:3139-3148.
• [33]Herold C, Ocker M, Ganslmayer M, Gerauer H, Hahn EG, Schuppan D: Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Br J Cancer 2002, 86:443-448.
• [34]Wang SW, Pan SL, Huang YC, Guh JH, Chiang PC, Huang DY, Kuo SC, Lee KH, Teng CM: CHM-1, a novel synthetic quinolone with potent and selective antimitotic antitumor activity against human hepatocellular carcinoma in vitro and in vivo. Mol Cancer Ther 2008, 7:350-360.